Table 2.
Treatment Characteristics of the Patients by Treatment Group
| Characteristic | Haloperidol (n = 23) | Risperidone (n = 52) | Olanzapine (n = 25) | χ22 or F2 | P |
| Neuroleptic dosage (mean CPZ equivalents/d ± SD) | 396.8 ± 196.1 | 329.8 ± 128.8 | 365.0 ± 154.2 | 1.87 | .159 |
| Concomitant medication | |||||
| Benzodiazepines, any, n (%) | 7 (30) | 19 (36) | 3 (12) | 4.96 | .083 |
| Antidepressants, any, n (%) | 1 (4) | 4 (8) | 5 (20) | 3.90 | .142 |
| Mood stabilizers, any, n (%) | 1 (4) | 6 (11) | 2 (8) | 1.04 | .592 |
| Biperiden, any, n (%) | 11 (48) | 13 (25) | 0 (0) | 15.08 | < .001a |
| Biperiden, mean mg/d ± SD | 2.00 ± 2.33 | 1.12 ± 2.03 | 0 (0) | 7.10 | < .001a |
| Biperiden, mean no. of days ± SD | 4.95 ± 6.71 | 2.92 ± 5.93 | 0 (0) | 5.24 | .007a |
a
Haloperidol > risperidone > olanzapine.
Abbreviation: CPZ = chlorpromazine.